Skip to main content
eScholarship
Open Access Publications from the University of California

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View